United States Drug Manufacturers - General news

17:13 21 Jul 2026

Amgen Market update Main company 🇺🇸 United States

More Than Dry Eyes: The Many Faces of Sjögren’s Disease

This article highlights the diverse manifestations of Sjögren's disease through the experiences of three women—Elaine, Courtney, and Rose—demonstrating that the autoimmune condition extends far beyond typical dry eyes and mouth. It explores the varied paths to diagnosis, the evolving and often debilitating symptoms like …

AMGN main company

Sharemaestro market context Trend signal active 52 weeks +44.4%

17:08 21 Jul 2026

Sharecast.com Regulatory and legal Main company 🇺🇸 United States

Novo Nordisk files lawsuit against Eli Lilly for 'misleading' weight-loss drug ads

Novo Nordisk has filed a lawsuit against Eli Lilly & Co in the US District Court in New Jersey, accusing the rival pharmaceutical company of using "misleading" and "deceptive" advertising for its weight-loss drugs. The suit alleges violations of federal and state false advertising …

LLY main company

Sharemaestro market context Trend signal active 52 weeks +66.6% · Next-week setup positive 58.3%

17:07 21 Jul 2026

TradingView Market update Main company 🇺🇸 United States

Discontinued operations of Biogen Inc. – BCS:BIIB0

This article from TradingView indicates that Biogen Inc.'s operations, specifically under the ticker BCS:BIIB0 on the Santiago Stock Exchange, have been discontinued. The page displays "No trades" and is focused on financial data and stock information for the company.

BIIB main company

Sharemaestro market context Trend signal active 52 weeks +50.6% · Next-week setup positive 55.3%

16:53 21 Jul 2026

Fierce Pharma Regulatory and legal Main company 🇺🇸 United States

Amgen agrees to $74M settlement to resolve investor lawsuit over potential $10.7B tax bill

Amgen has reached a $74 million settlement with investors who accused the company of concealing a potential $10.7 billion U.S. tax bill, which they claimed artificially inflated Amgen's share price. The settlement, filed in federal court, does not include an admission of liability from …

AMGN main company

Sharemaestro market context Trend signal active 52 weeks +44.4%

16:50 21 Jul 2026

finance.yahoo.com Earnings Main company 🇺🇸 United States

Eli Lilly (LLY): Buy, Sell, or Hold Post Q1 Earnings?

Eli Lilly (LLY): Buy, Sell, or Hold Post Q1 Earnings? Eli Lilly has followed the market's trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 6.5% to $1,149 per share while the index has …

LLY main company

Sharemaestro market context Trend signal active 52 weeks +66.6% · Next-week setup positive 58.3%

16:41 21 Jul 2026

finance.yahoo.com Deals and strategy Main company 🇺🇸 United States

Novartis Q2 Earnings & Revenues Top Estimates, Key Drugs Perform Well

Swiss pharma giant Novartis AG NVS reported second-quarter core earnings per share (excluding one-time charges) of $2.41, which comfortably beat the Zacks Consensus Estimate of $2.20. The figure was, however, down from $2.42 reported a year ago due to lower core net income. Revenues …

NVS main company

Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2%

16:33 21 Jul 2026

finance.yahoo.com Regulatory and legal Main company 🇺🇸 United States

Novo Sues Lilly Over Weight-Loss Ad Claims

This article first appeared on GuruFocus. Novo Nordisk (NOVO_B) filed a lawsuit accusing Eli Lilly (NYSE:LLY) of running a "deliberately false" advertising campaign about the comparative effectiveness of their competing obesity and diabetes drugs. Novo Nordisk alleges Lilly cited outdated clinical trial data to …

NVO main company

Sharemaestro market context Trend signal started 52 weeks -16.7%

16:25 21 Jul 2026

Fierce Pharma Market update Main company 🇺🇸 United States

Lilly, BMS aerospace partner Redwire opens new site in Indiana

Aerospace technology company Redwire, a partner to Bristol Myers Squibb and Eli Lilly for drug manufacturing research in space, has opened a new 30,000 square foot facility in Georgetown, Indiana. This site will serve as Redwire's global hub for expanding space-enabled R&D and manufacturing, …

LLY main company

Sharemaestro market context Trend signal active 52 weeks +66.6% · Next-week setup positive 58.3%

16:17 21 Jul 2026

Reuters Regulatory and legal Main company 🇺🇸 United States

Amgen settles shareholder lawsuit claiming it hid $10.7 billion tax bill

Amgen has agreed to a $74 million settlement in a shareholder lawsuit. The lawsuit alleged that the biotechnology company delayed disclosing a potential $10.7 billion tax liability to the IRS for underreporting taxes between 2010 and 2015, primarily due to improper profit shifting to …

AMGN main company

Sharemaestro market context Trend signal active 52 weeks +44.4%

16:09 21 Jul 2026

BioPharma Dive Earnings Main company 🇺🇸 United States

Novartis climbs on upbeat drug sales as key readouts loom

Novartis reported stronger-than-expected second-quarter sales and core operating income, driven by newer "priority brands" like Kisqali, Kesimpta, and Scemblix, despite a significant drop in revenue for its former top-seller, Entresto, due to generic competition. The company is preparing for upcoming patent expirations on several …

NVS main company

Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2%

16:08 21 Jul 2026

Morningstar Market update Main company 🇺🇸 United States

Eli Lilly's Dominance in a Massive GLP-1 Market Provides Opportunity to Invest in Pipeline

Eli Lilly's innovative culture and strong financial commitment to drug development position it for significant long-term growth, especially within the GLP-1 market. The company is launching several new blockbusters, and fading patent losses further support its industry-leading growth potential. This dominance in a massive …

LLY main company

Sharemaestro market context Trend signal active 52 weeks +66.6% · Next-week setup positive 58.3%

16:08 21 Jul 2026

MarketWatch Regulatory and legal Main company 🇺🇸 United States

Novo Nordisk’s lawsuit against Eli Lilly over ads highlights intense competition in GLP-1 market

Novo Nordisk has filed a lawsuit against Eli Lilly, accusing its primary competitor of running deceptive advertisements for its GLP-1 medications, Zepbound and Mounjaro. Novo Nordisk claims that Lilly's ads unfairly compare their drugs by omitting crucial information about the most effective doses of …

LLY main company

Sharemaestro market context Trend signal active 52 weeks +66.6% · Next-week setup positive 58.3%

16:08 21 Jul 2026

The Globe and Mail Regulatory and legal Main company 🇺🇸 United States

Novo Nordisk sues Eli Lilly in U.S. court, claiming deceptive weight-loss ads

Novo Nordisk has filed a lawsuit against Eli Lilly in U.S. federal court, alleging false advertising regarding the efficacy of Lilly's weight-loss medicines. Novo claims that Lilly's ads deceptively compare its drugs to lower, outdated doses of Novo's Wegovy and Ozempic, omitting newer, higher-dose …

LLY main company

Sharemaestro market context Trend signal active 52 weeks +66.6% · Next-week setup positive 58.3%

16:07 21 Jul 2026

finance.yahoo.com Earnings Main company 🇺🇸 United States

Novartis Q2 Earnings Call Highlights

Key Points Interested in Novartis AG? Here are five stocks we like better. Novartis returned to sales growth in Q2 2026, with net sales up 1% in constant currency to $14.4 billion and free cash flow of $5.6 billion. The company reaffirmed its full-year …

NVS main company

Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2%

16:01 21 Jul 2026

24/7 Wall St. Deals and strategy Main company 🇺🇸 United States

Johnson & Johnson vs Abbott Laboratories: Two Healthcare Giants on Opposite Trajectories

Johnson & Johnson (JNJ) and Abbott Laboratories (ABT) are moving in opposite strategic directions, with JNJ focusing on pruning its portfolio by spinning off Orthopaedics, while ABT is expanding through its $21 billion Exact Sciences acquisition. JNJ's oncology segment shows strong momentum, while Abbott's …

JNJ main company

Sharemaestro market context Trend signal active 52 weeks +48.8%

15:30 21 Jul 2026

nasdaq.com Earnings Main company 🇺🇸 United States

Nasdaq 100 Movers: TRI, SNDK

In early trading on Tuesday, shares of SanDisk topped the list of the day's best performing components of the Nasdaq 100 index, trading up 9.7%. Year to date, SanDisk registers a 542.7% gain. And the worst performing Nasdaq 100 component thus far on the …

GILD main company

Sharemaestro market context Price above Trend Line 52 weeks +23.7%

15:19 21 Jul 2026

finance.yahoo.com Market update Main company 🇺🇸 United States

Novartis Is On The Rise. But So, Too, Are Its Generic Rivals.

Novartis stock popped Tuesday on a solid second-quarter report, despite feeling continued heat from generic rivals for big-name drugs. Continue Reading

NVS main company

Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2%

15:17 21 Jul 2026

finance.yahoo.com Earnings Main company 🇺🇸 United States

GLP-1 Titans Clash: Comparing Eli Lilly and Novo Nordisk

Novo Nordisk NVO and Eli Lilly LLY lead the diabetes and obesity market, driven by their blockbuster GLP-1 therapies. Lilly sells its dual GIP/GLP-1 agonist tirzepatide as Mounjaro for type II diabetes and as Zepbound for obesity. Novo Nordisk markets semaglutide as Ozempic and …

NVO main company

Sharemaestro market context Trend signal started 52 weeks -16.7%

15:11 21 Jul 2026

Benzinga Earnings Main company 🇺🇸 United States

Novartis Q2 2026 Earnings Call Transcript

Novartis reported a 1% net sales growth in Q2 2026, reaching $14.4 billion, with core operating income remaining flat at $5.9 billion. The company reaffirmed its full-year 2026 guidance, expecting low single-digit net sales growth and a decline in core operating income, driven by …

NVS main company

Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2%

15:10 21 Jul 2026

GuruFocus Earnings Main company 🇺🇸 United States

GSK Unveils New Data on Long-Acting HIV Treatments Ahead of AIDS Conference

GSK PLC (NYSE: GSK) announced new data from its subsidiary ViiV Healthcare regarding long-acting HIV treatments, to be presented at the 26th International AIDS Conference. The studies include findings on two-drug and long-acting injectable regimens, aiming to advance HIV treatment options. GSK's current P/E …

GSK main company

Sharemaestro market context Price below Trend Line 52 weeks +26.3% · Next-week setup positive 55.6%

15:08 21 Jul 2026

FXStreet Guidance Main company 🇺🇸 United States

Eli Lilly and Company (LLY) forecast: Bulls watching the $1074–$1003 support zone

Eli Lilly and Company (LLY) is expected to experience a corrective pullback within a bullish impulse sequence. Analysts predict a buying opportunity between $1073.94 and $1002.88, where the stock is expected to find support before continuing its rally. The forecast is based on Elliott …

LLY main company

Sharemaestro market context Trend signal active 52 weeks +66.6% · Next-week setup positive 58.3%

15:08 21 Jul 2026

Новости GxP Earnings Main company 🇺🇸 United States

How Dave Ricks transformed Eli Lilly – and the perils of the obesity drug boom

Under CEO Dave Ricks, Eli Lilly has undergone a significant transformation, growing its market capitalization 14-fold and becoming a global powerhouse, largely thanks to its successful obesity drugs Mounjaro and Zepbound. Ricks sped up drug development, invested heavily in manufacturing, and strategized to compete …

LLY main company

Sharemaestro market context Trend signal active 52 weeks +66.6% · Next-week setup positive 58.3%

15:07 21 Jul 2026

Investing.com Earnings Main company 🇺🇸 United States

BofA cuts Biogen stock price target on higher expectations bar

BofA Securities has lowered its price target for Biogen Inc. (NASDAQ:BIIB) to $215 from $217, maintaining a Neutral rating, citing a higher bar for sustaining momentum after recent strong performance. Despite the cut, the stock has seen a 63% return over the past year …

BIIB main company

Sharemaestro market context Trend signal active 52 weeks +50.6% · Next-week setup positive 55.3%

15:01 21 Jul 2026

finance.yahoo.com Regulatory and legal Main company 🇺🇸 United States

Weight-loss wars: Why Novo Nordisk is suing Eli Lilly

Novo Nordisk (NVO) is suing Eli Lilly (LLY) for misleading advertising. Morning Brief host Julie Hyman discusses the details with Yahoo Finance Breaking Business News Reporter Jake Conley and Payne Capital Management president Ryan Payne. Video Transcript 00:00 Speaker A Novo Nordisk is filing …

NVO main company

Sharemaestro market context Trend signal started 52 weeks -16.7%

15:00 21 Jul 2026

Fierce Pharma Market update Main company 🇺🇸 United States

Gilead, Merck’s phase 3 data back first weekly HIV pill

New phase 3 data from two Islend clinical trials indicate that the experimental once-weekly, single-tablet combination of Gilead’s lenacapavir and Merck’s islatravir (ISL/LEN) effectively maintains HIV viral suppression, matching daily treatments like Gilead’s Biktarvy. If approved, ISL/LEN would be the first complete weekly oral …

MRK main company GILD main company

Sharemaestro market context Trend signal active 52 weeks +60.7%

15:00 21 Jul 2026

finance.yahoo.com Earnings Main company 🇺🇸 United States

Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure

– Long-Term Data from the PURPOSE 1 and PURPOSE 2 Trials Demonstrate Continued High Efficacy, High Adherence and Consistent Safety Profile of Twice-Yearly Lenacapavir for PrEP – – Detailed Phase 3 Results from the ISLEND-1 and ISLEND-2 Trials Highlight the Potential of Weekly HIV …

GILD main company

Sharemaestro market context Price above Trend Line 52 weeks +23.7%

14:50 21 Jul 2026

finance.yahoo.com Market update Main company 🇺🇸 United States

Why Agios Pharma, A Novo Rival, Just Pulled A Bearish Move

Agios Pharmaceuticals dropped its next-generation sickle cell drug Tuesday after a failed Phase 2 study. Agios stock tumbled. Continue Reading

NVO main company

Sharemaestro market context Trend signal started 52 weeks -16.7%

14:38 21 Jul 2026

TradingView Earnings Main company 🇺🇸 United States

What to Watch in Pfizer's Non-Oncology Portfolio This Earnings Season

This article previews Pfizer's second-quarter 2026 earnings, focusing on the expected performance of its non-oncology segments. It highlights key products like Eliquis, Prevnar, Comirnaty, Paxlovid, Abrysvo, Vyndaqel, and Xeljanz, detailing projected sales trends. The piece also touches on Pfizer's competitive landscape, stock performance, and …

PFE main company

Sharemaestro market context Price above Trend Line 52 weeks +8.9%

14:30 21 Jul 2026

finance.yahoo.com Earnings Main company 🇺🇸 United States

Compared to Estimates, Novartis (NVS) Q2 Earnings: A Look at Key Metrics

For the quarter ended June 2026, Novartis (NVS) reported revenue of $14.41 billion, up 2.5% over the same period last year. EPS came in at $2.41, compared to $2.42 in the year-ago quarter. The reported revenue represents a surprise of +3.3% over the Zacks …

NVS main company

Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2%

14:24 21 Jul 2026

finance.yahoo.com Earnings Main company 🇺🇸 United States

Novartis Q2 2026 earnings beat as cancer, MS drugs drive growth

Novartis reported second-quarter net sales of $14.4 billion on Tuesday, up 3% in dollar terms and 1% in constant currencies, as strong demand for cancer and multiple sclerosis treatments helped the Swiss drugmaker return to sales growth despite a steep drop in its top-selling …

NVS main company

Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2%

14:22 21 Jul 2026

finance.yahoo.com Earnings Main company 🇺🇸 United States

U.S. stocks set for higher open as strong earnings boost market sentiment: Dow Jones, S&P, Nasdaq, Wall Street Futures

Wall Street bull ©Shutterstock Earnings optimism supports pre-market gains U.S. stock futures pointed to a firmer open on Tuesday as investors looked to recover from the previous session's decline, with upbeat corporate earnings encouraging buying across several sectors. Market sentiment improved after a series …

NVS main company

Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2%

14:08 21 Jul 2026

TradingView Earnings Main company 🇺🇸 United States

Net income of Pfizer Inc. – BCS:PFECL1

The article provides a title related to the net income of Pfizer Inc. with the stock symbol BCS:PFECL1. It indicates that the market for this particular stock on the Santiago Stock Exchange was closed with no trades. The content is mostly boilerplate from TradingView, …

PFE main company

Sharemaestro market context Price above Trend Line 52 weeks +8.9%

14:08 21 Jul 2026

Moomoo Deals and strategy Main company 🇺🇸 United States

Press Release: Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio

Gilead Sciences has announced the completion of its strategic acquisition of Tubulis, a German-based biotechnology company. This acquisition is set to enhance Gilead's oncology portfolio, particularly in the area of antibody-drug conjugates (ADCs) for cancer treatment. The integration of Tubulis's innovative ADC platform and …

GILD main company

Sharemaestro market context Price above Trend Line 52 weeks +23.7%

14:00 21 Jul 2026

finance.yahoo.com Earnings Main company 🇺🇸 United States

Is Most-Watched Stock Novo Nordisk A/S (NVO) Worth Betting on Now?

Novo Nordisk (NVO) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Over the past month, shares of this drugmaker have …

NVO main company

Sharemaestro market context Trend signal started 52 weeks -16.7%

13:59 21 Jul 2026

finance.yahoo.com Market update Main company 🇺🇸 United States

Pharma heavyweights clash over anti-obesity drug ads

Anti-obesity treatments have been a financial windfall for Novo Nordisk and Eli Lily (SEBASTIEN BOZON) Danish pharmaceuticals heavyweight Novo Nordisk said Tuesday it is suing its arch US rival, Eli Lilly, over "false and materially misleading" adverts for their competing weight-loss and anti-diabetes treatments. …

NVO main company

Sharemaestro market context Trend signal started 52 weeks -16.7%

13:56 21 Jul 2026

finance.yahoo.com Earnings Main company 🇺🇸 United States

Gilead Sciences' Quarterly Earnings Preview: What You Need to Know

Gilead sign is seen during the fifth China International Import Expo By Eagle Gilead Sciences, Inc. (GILD), headquartered in Foster City, California, is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical need. Valued at $166.7 billion by …

GILD main company

Sharemaestro market context Price above Trend Line 52 weeks +23.7%